Search results
Clinical trial for methamphetamine withdrawal treatment
Cosmos· 5 hours agoAustralian researchers have been awarded $2.2 million to trial a stimulant medication for the...
Psychostimulant No Help in Relieving Cancer-Related Fatigue
MedPage Today· 5 days agoThe psychostimulant methylphenidate proved no better than placebo for relieving cancer-related...
Mindful Living: Strategies to Prevent Cognitive Decline
Medscape· 3 days agoCognitive impairment, or loss of memory and thinking skills, is a hallmark feature of Alzheimer's...
JSYK, Timing Is *Key* When Taking a Magnesium Supplement
Cosmopolitan via AOL· 2 days agoPlus, depression has been associated with lower magnesium levels, and supplementing with magnesium...
Wellbutrin vs Adderall: What They Treat & Other Diffferences
MediaFeed via AOL· 5 days agoAnxiety and depression are two common mental conditions — it’s estimated that about 40 million...
Can grapefruit juice lower blood pressure?
Winston-Salem Journal· 3 days agoQ. I have been taking amlodipine and benazepril for many years to lower my blood pressure. Two days ago, I decided to skip the meds and try a grapefruit...
Exercise Improves Sexual Health in Metastatic Breast Cancer
Medscape· 5 days agoExercise can help improve sexual health in women with metastatic breast cancer and should be a key...
Semaglutide Kidney Benefits Extend to Those Without Diabetes
Medscape· 20 hours agoImprovements in kidney function outcomes observed with glucagon-like peptide-1 (GLP-1) receptor...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 4 days agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...
...dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and...
Benzinga· 6 days agoNOTUS results confirm landmark data from the Phase 3 BOREAS trial and show Dupixent significantly reduced exacerbations by 34% and improved lung function, compared to placebo, in uncontrolled chronic obstructive